Metformin

Data show Black adults with type 2 diabetes and moderate chronic kidney disease were significantly less likely to receive a metformin prescription compared with white counterparts under an old FDA serum creatinine-based metformin label.

Nostrum Laboratories, Inc., is voluntarily recalling two lots of metformin hydrochloride extended-release tablets that contain unacceptable levels of the nitrosamine impurity N-Nitrosodimethylamine, or NDMA, according to an FDA statement.

Results from a randomized controlled trial showed that metformin provided cardiovascular benefits to patients with chronic kidney disease and metabolic syndrome.

The FDA has asked five drug manufacturers to voluntarily recall several lots of extended-release metformin after agency lab testing revealed unacceptable levels of the nitrosamine impurity N-Nitrosodimethylamine, or NDMA.

Analyses of data from two clinical trials and a real-world study revealed an increased risk for anemia among adults with type 2 diabetes prescribed metformin.

According to findings from a pilot study, adults with type 2 diabetes who replaced their usual meals with nutritional shakes experienced a 47% reduction in post-meal peak glucose.

The antidiabetic drug metformin decreases weight and modifies the gut microbiota in patients with HIV who do not have diabetes, according to a study published in Open Forum Infectious Diseases.

Women with polycystic ovary syndrome and overweight or obesity who underwent fertility treatment had a higher clinical pregnancy rate when assigned metformin vs. similar women not taking the medication, according to a meta-analysis.

The FDA has requested a voluntary recall of several lots of extended-release metformin. It was the top story in endocrinology last week.

Patients with type 2 diabetes who were prescribed metformin prior to a major surgery had reduced risks for mortality and readmission in the 90 days following the procedure, according to a retrospective cohort study published in JAMA Surgery.